185 related articles for article (PubMed ID: 16945774)
1. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab.
Platini C; Long J; Walter S
Lancet Oncol; 2006 Sep; 7(9):778-80. PubMed ID: 16945774
[No Abstract] [Full Text] [Related]
2. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
[TBL] [Abstract][Full Text] [Related]
3. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.
Mir O; Ropert S; Alexandre J; Lemare F; Goldwasser F
Ann Oncol; 2008 Nov; 19(11):1978-80. PubMed ID: 18845838
[No Abstract] [Full Text] [Related]
4. Intrathecal trastuzumab: dose matters.
Hofer S; Mengele K; Stemmler HJ; Schmitt M; Pestalozzi B
Acta Oncol; 2012 Sep; 51(7):955-6. PubMed ID: 22524214
[No Abstract] [Full Text] [Related]
5. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
[TBL] [Abstract][Full Text] [Related]
6. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab.
Colozza M; Minenza E; Gori S; Fenocchio D; Paolucci C; Aristei C; Floridi P
Cancer Chemother Pharmacol; 2009 May; 63(6):1157-9. PubMed ID: 18987856
[No Abstract] [Full Text] [Related]
7. Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab.
Baculi RH; Suki S; Nisbett J; Leeds N; Groves M
J Clin Oncol; 2001 Jul; 19(13):3297-8. PubMed ID: 11432901
[No Abstract] [Full Text] [Related]
8. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis.
Laufman LR; Forsthoefel KF
Clin Breast Cancer; 2001 Oct; 2(3):235. PubMed ID: 11899418
[No Abstract] [Full Text] [Related]
9. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer.
Ferrario C; Davidson A; Bouganim N; Aloyz R; Panasci LC
Ann Oncol; 2009 Apr; 20(4):792-5. PubMed ID: 19223574
[No Abstract] [Full Text] [Related]
11. Correction: Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab.
Pestalozzi BC
J Clin Oncol; 2001 Oct; 19(20):4091. PubMed ID: 11600616
[No Abstract] [Full Text] [Related]
12. [Trastuzumab and blood-brain barrier].
Platini C
Bull Cancer; 2007 Oct; 94(10):857-9. PubMed ID: 17964978
[TBL] [Abstract][Full Text] [Related]
13. [Trastuzumab's association with cerebral metastases and meningeal carcinomatosis in a patient with HER2-positive breast cancer].
Ayuga Loro F; Jiménez Caballero PE; Martínez Barbeito MB; Cruz Mora MA
Med Clin (Barc); 2009 Jul; 133(7):279-80. PubMed ID: 19615485
[No Abstract] [Full Text] [Related]
14. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy.
Rogers LR; Remer SE; Tejwani S
Neuro Oncol; 2004 Jan; 6(1):63-4. PubMed ID: 14769142
[TBL] [Abstract][Full Text] [Related]
15. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
[TBL] [Abstract][Full Text] [Related]
16. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases.
Martens J; Venuturumilli P; Corbets L; Bestul D
Acta Oncol; 2013 Jan; 52(1):175-8. PubMed ID: 22655969
[No Abstract] [Full Text] [Related]
17. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
[No Abstract] [Full Text] [Related]
18. Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?
Bozovic-Spasojevic I; Azim HA; Paesmans M; Suter T; Piccart MJ; de Azambuja E
Lancet Oncol; 2011 Mar; 12(3):209-11. PubMed ID: 21354372
[No Abstract] [Full Text] [Related]
19. Meningeal carcinomatosis in HER2-overexpressing breast cancers.
Bidard FC; Guilhaume MN; Gauthier H; Cottu PH; Diéras V; Pierga JY
J Neurooncol; 2009 Jun; 93(2):287-8. PubMed ID: 19139826
[No Abstract] [Full Text] [Related]
20. [Trastuzumab for treatment of advanced breast cancers].
Watanabe T; Shimizu C; Katsumata N; Saijo N
Nihon Rinsho; 2000 Apr; 58 Suppl():340-4. PubMed ID: 11026016
[No Abstract] [Full Text] [Related]
[Next] [New Search]
